BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petroni G, Buqué A, Coussens LM, Galluzzi L. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat Rev Drug Discov 2022. [PMID: 35292771 DOI: 10.1038/s41573-022-00415-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Fu J, Wang S, Li Z, Qin W, Tong Q, Liu C, Wang Z, Liu Z, Xu X. Comprehensive multiomics analysis of cuproptosis-related gene characteristics in hepatocellular carcinoma. Front Genet 2022;13:942387. [DOI: 10.3389/fgene.2022.942387] [Reference Citation Analysis]
2 Zhang T, Zhang C, Fu Z, Gao Q. Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy. Pharmaceutics 2022;14:1768. [DOI: 10.3390/pharmaceutics14091768] [Reference Citation Analysis]
3 Aramini B, Masciale V, Samarelli AV, Dubini A, Gaudio M, Stella F, Morandi U, Dominici M, De Biasi S, Gibellini L, Cossarizza A. Phenotypic, functional, and metabolic heterogeneity of immune cells infiltrating non–small cell lung cancer. Front Immunol 2022;13:959114. [DOI: 10.3389/fimmu.2022.959114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Marchi S, Guilbaud E, Tait SWG, Yamazaki T, Galluzzi L. Mitochondrial control of inflammation. Nat Rev Immunol 2022. [PMID: 35879417 DOI: 10.1038/s41577-022-00760-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, Berneman ZN, Beuselinck B, Bol KF, Borst J, Coosemans A, Datsi A, Fučíková J, Kinget L, Neyns B, Schreibelt G, Smits E, Sorg RV, Spisek R, Thielemans K, Tuyaerts S, De Vleeschouwer S, de Vries IJM, Xiao Y, Garg AD. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology 2022;11:2096363. [DOI: 10.1080/2162402x.2022.2096363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Morimoto Y, Fushimi A, Yamashita N, Hagiwara M, Bhattacharya A, Cheng J, Frost TC, Ahmad R, Daimon T, Huang L, Hata T, Takahashi H, Yamamoto M, Suzuki Y, DeCaprio JA, Kufe D. Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment. Oncogene 2022. [PMID: 35688945 DOI: 10.1038/s41388-022-02361-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]